Apixaban is currently the most prescribed oral anticoagulant in the general population and in people with HIV. For people with HIV and atrial fibrillation (Afib or AF), ...

Apixaban is a direct-acting oral anticoagulant that has an excellent risk–benefit profile for stroke prevention among patients with clinical atrial fibrillation. 3,5 The Apixaban for the ...

Apixaban oral tablet is a prescription drug used to treat and prevent blood clots such as deep vein thrombosis (DVT) and pulmonary embolism (PE). It also helps decrease risk of stroke in atrial ...

Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine , 2011; 110827230022006 DOI: 10.1056/NEJMoa1107039 Cite This Page : ...

With the recent approval of apixaban for stroke prevention in AF, all 3 of the new oral anticoagulants are now available, leaving doctors with the dilemma of which one to use in which patients.

Apixaban was also associated with a 49% lower risk of gastrointestinal or intracranial bleeding vs rivaroxaban (HR, 0.51; 95% CI, 0.41-0.62).

Although apixaban caused much lower rates of major bleeding in frail patients when compared to Coumadin (eg, 40.7 such events per 1,000 person-years for dabigatran and 83.4 such events per 1,000 ...

The trial enrolled patients with cryptogenic stroke and evidence suggestive of atrial cardiopathy, but no evidence of atrial fibrillation, who were randomized to apixaban, 5 mg or 2.5 mg twice ...

Apixaban is a substrate of P-glycoprotein and P-glycoprotein inhibition increases drug exposure. Bleeding risk does not appear to increase when apixaban is given concomitantly with cardiac P ...

We conducted the Apixaban Cancer Associated Thrombosis (API-CAT) trial to assess whether a reduced-dose regimen of apixaban (2.5 mg twice daily) would be noninferior to a full-dose regimen (5.0 mg ...

Apixaban may be available through a mail-order pharmacy. Using this type of service may help lower the drug’s cost and allow you to receive your medication without leaving home.

Rivaroxaban (Xarelto) was also associated with higher risk than apixaban (42.94 vs 20.05 per 1,000 person-years, HR 2.15, 95% ...